The positive mental health results being produced by mind-altering treatments simply can’t be ignored any longer.
Which is why Health Canada just approved hallucinogens like molly and magic mushrooms to be used for medical purposes.1
It’s also why a New York lawmaker has filed a bill to legalize medical psilocybin treatments.2
And why, just one day earlier, Seattle’s City Council approved a resolution to decriminalize a wide range of activities around mind-altering medicine – “including the cultivation and sharing of psilocybin mushrooms.”3
It’s clear that the times are changing – and investors who act fast with potential breakout companies like Numinus Wellness Inc. (TSX:NUMI) could get in on the ground floor of the next medical revolution.
Healthcare advocates are calling Health Canada’s approval a major breakthrough in treating serious and life-threatening conditions.
“This is the greatest leap forward in mental-health care since the invention of psychotherapy,” said Edmonton-based psychologist Brian Welling.4
Meanwhile in America, The New York Times just reported that “The Hallucinogenic Revolution Is Coming” and even said that “Mushrooms and molly are poised to be the hottest new therapeutics since Prozac.”5
In other words, there hasn’t been an opportunity like this for investors since medical MJ exploded on the scene several years ago. In fact, hallucinogenic-assisted psychotherapies are now being called “the mental MMJ” of the future.
Why Hallucinogenics? And Why Now?
Mental illness has reached crisis proportions and hallucinogenics are emerging as a new category of medicine that shows tremendous treatment promise.
That, in a nutshell, is why both the Canadian and US governments are easing restrictions on their use.
There’s also growing support for hallucinogenics from scientific communities who are intensely studying this new medication category.
At the Centre for [hallucinogenics] Research at Imperial College in London, the first of its kind, they have been researching how acid, psilocybin, N,N-Dimethyltryptamine, and molly impact the brain, and how they may help treat disorders such as depression.
Meanwhile, John Hopkins Center for [Hallucinogenics] and Consciousness Research in Baltimore is studying psilocybin as a treatment for everything from Alzheimer’s disease and PTSD to smoking and anorexia. The center has several notable achievements6 so far and $17 million in funding from private donors, making it the largest hallucinogenics research center in the world and the first of its kind in the US.
With government restrictions easing and positive study results starting to pour in, it is likely only a matter of time before hallucinogenics become an in-demand treatment for traumatic brain injury, depression, anxiety, PTSD, addiction, and more.
That is going to put companies like Numinus Wellness Inc. (TSX:NUMI) in high demand.
Who is Numinus Wellness?
Numinus Wellness Inc. (TSX:NUMI) is a leader in hallucinogenics-focused mental healthcare and the first public company in Canada to receive a license to produce and extract psilocybin from mushrooms.
Numinus made history when it became the first public company to partner with hallucinogenics pioneer MAPS (the Multidisciplinary Association for Hallucinogenics Studies) on Canada’s first compassionate access trial of molly for PTSD. And the company has continued to make serious headway ever since.
On January 19, Numinus completed key steps in the MAPS-sponsored “A multi-site open-label extension study of Molly-assisted psychotherapy for PTSD (MAPPUSX)7.
The study sites just received approvals from both Health Canada and the Institutional Review Board (IRB) and is now ready to enroll participants at its clinics.
On top of that, Numinus Wellness Inc. (TSX:NUMI) just submitted a clinical trial application to Health Canada to evaluate its first trademarked product and patent-pending production process – a milestone that progresses and solidifies the company’s long-standing work developing safe and effective mind-altering products out of its Health Canada-licensed research facility, Numinus Bioscience.8
And with its ability to cultivate and harvest and from there, develop new formulations for products in clinical trials, it’s clear that Numinus Wellness Inc. has a first-mover advantage. Not only can the company create new innovative products, but by having a dealer’s license, it also has the ability to import, export, possess, test, and distribute molly, psilocybin, psilocin, N,N-Dimethyltryptamine, and mescaline.
Hallucinogenics represent a massive opportunity and Numinus Wellness Inc. (TSX:NUMI) is the ideal candidate for major health companies to form partnerships, hire contract research services, or engage in analytics and testing services. The company’s diverse, multidisciplinary approach puts Numinus front and center with its unique suite of offerings.
Numinus Has Two More Things Working in its Favor:
- Impressive Leadership
The company’s team includes Payton Nyquvest, co-founder & chief executive officer and Dr. Evan Wood. Payton brings 15+ years experience in Canada/US capital markets, including raises for early MMJ. He also raised $100M+ for public and private companies and was a former VP and Head of Sales for one of Canada’s largest independent brokerages. Then, there’s Chief Medical Officer Evan Wood, a research leader on addiction medicine and driver of major health policy reform.
- A Strong Financial Foundation
Numinus Wellness Inc. (TSX:NUMI) went public last year, after raising an initial $10M with institutional support from Canaccord Genuity and Eight Capital. The company then closed an oversubscribed financing for an additional $17M and a $40M bought deal financing in March 2021.9
And it’s only been uphill from there. Numinus just reported outstanding Q4 and FY 2021 results that included:
- A strong year-end cash position of $59.2 million
- Revenues that grew 81% year-over-year to $0.5 million for Q4 2021
- Revenues that grew 72% year-over-year to $1.5 million for FY 2021
Then on December 16, Numinus Wellness Inc. (TSX:NUMI) graduated to the Toronto Stock Exchange.
Combine the two revenue streams with a very strong financial position and positive recent developments like the move to the TSX and it starts to become very clear why we’re so excited about this company!
To start doing your due diligence on this potential breakout company, check out our full report by clicking on the link below.
Click on the link below to learn much more about Numinus Wellness Inc. (TSX:NUMI) and the hallucinogenics market.
Yes, I want to learn all about Numinus Wellness & the future of hallucinogenics!